Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Retained Earnings (2016 - 2025)

Rocket Pharmaceuticals (RCKT) has disclosed Retained Earnings for 10 consecutive years, with -$31000.0 as the latest value for Q4 2025.

  • Quarterly Retained Earnings fell 146.97% to -$31000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$31000.0 through Dec 2025, down 146.97% year-over-year, with the annual reading at -$31000.0 for FY2025, 146.97% down from the prior year.
  • Retained Earnings hit -$31000.0 in Q4 2025 for Rocket Pharmaceuticals, down from -$9000.0 in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $213000.0 in Q3 2024 to a low of -$1.3 billion in Q2 2025.
  • Historically, Retained Earnings has averaged -$391.3 million across 5 years, with a median of -$743500.0 in 2022.
  • Biggest five-year swings in Retained Earnings: plummeted 667013.4% in 2022 and later soared 100.02% in 2024.
  • Year by year, Retained Earnings stood at -$161000.0 in 2021, then tumbled by 121.74% to -$357000.0 in 2022, then tumbled by 268631.09% to -$959.4 million in 2023, then soared by 100.01% to $66000.0 in 2024, then plummeted by 146.97% to -$31000.0 in 2025.
  • Business Quant data shows Retained Earnings for RCKT at -$31000.0 in Q4 2025, -$9000.0 in Q3 2025, and -$1.3 billion in Q2 2025.